35031-00-6

Basic information

• Product Name: ethyl 2-hydroxy-4-methoxybenzoate
• Synonyms: ethyl 2-hydroxy-4-methoxybenzoate
• CAS NO: 35031-00-6
• Molecular Weight: 196.203
• Mol File: 35031-00-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: ethyl 2-hydroxy-4-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-hydroxy-4-methoxybenzoate(35031-00-6)
• EPA Substance Registry System: ethyl 2-hydroxy-4-methoxybenzoate(35031-00-6)

Safety Data

• Hazardous Substances Data: 35031-00-6(Hazardous Substances Data)

Upstream product

• 1264712-00-6 2-(2-bromo-5-methoxyphenoxy)-tetrahydropyran 
• 63604-94-4 2-bromo-5-methoxyphenol 
• 94-30-4 ethyl 4-methoxybenzoate 
• 89-86-1 4-hydroxysalicylic acid 
• 35030-97-8 ethyl 3-methoxyphenyl carbonate 
• 64-17-5 ethanol 
• 2237-36-7 4-methoxysalicylic acid 

Downstream Products

• 860696-37-3 2-ethoxycarbonylmethoxy-4-methoxy-benzoic acid ethyl ester 
• 41697-08-9 2-hydroxy-4-methoxybenzohydrazide 
• 1257843-08-5 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-5-methoxyphenol 
• 1357083-13-6 2-(5-(benzylthio)-1,3,4-oxadiazol-2-yl)-5-methoxyphenol 
• 58629-13-3 3-benzothiazol-2-yl-7-hydroxy-chromen-4-one 
• 1429183-45-8 5-Methoxy-2-(5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazol-2-yl)phenol 
• 126809-68-5 2-(methoxymethoxy)-4-methoxybenzyl alcohol 
• 53694-69-2 α,α-diphenyl-4-methoxysalicyl alcohol 
• 109142-71-4 methoxy-5 (carbethoxy-2 phenoxy)-acetate de methyle 
• 1378258-52-6 5-methoxy-2-(5-((4-nitrobenzyl)thio)-1,3,4-oxadiazol-2-yl)phenol 
• 1378258-48-0 5-methoxy-2-(5-((3-nitrobenzyl)thio)-1,3,4-oxadiazol-2-yl)phenol 
• 1378258-47-9 5-methoxy-2-(5-((2-nitrobenzyl)thio)-1,3,4-oxadiazol-2-yl)phenol 
• 1378258-45-7 5-methoxy-2-(5-((4-methoxybenzyl)thio)-1,3,4-oxadiazol-2-yl)phenol 

Relevant articles and documents

Gold (I) phosphine complex containing 5-phenyl-1, 3, 4-oxadiazole-2-thione and preparation method and application of gold (I) phosphine complex

The invention discloses a gold (I) phosphine complex containing 5-phenyl-1, 3, 4-oxadiazole-2-thione and a preparation method and application of the gold (I) phosphine complex, and belongs to the technical field of inorganic medicinal chemistry. The struc

Synthesis of Phenanthrene Derivatives by Intramolecular Cyclization Utilizing the [1,2]-Phospha-Brook Rearrangement Catalyzed by a Bronsted Base

The synthesis of functionalized phenanthrene derivatives was achieved by intramolecular cyclization utilizing the [1,2]-phospha-Brook rearrangement under Bronsted base catalysis. Treatment of biaryl compounds having an α-ketoester moiety and an alkyne moiety at the 2 and 2′ positions, respectively, with diisopropyl phosphite in the presence of a catalytic amount of phosphazene base P2-tBu provides 9,10-disubstituted phenanthrene derivatives in high yields. This reaction involves the generation of an ester enolate through an umpolung process, that is, addition of diisopropyl phosphite to a keto moiety followed by the [1,2]-phospha-Brook rearrangement, the intramolecular addition to an alkyne, and the [3,3] rearrangement of the allylic phosphate moiety in a consecutive fashion.

Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 ± 0.2, 30.0 ± 1.2, 18.3 ± 1.4 μM, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 μM, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 μg/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study.